Capital Expenditures for Incyte (INCY)
According to Incyte's latest reported financial statements, the company's current capital expenditures (TTM) is $65.90M USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
INCY
Currently viewingCapital ExpendituresSwitch metric
Latest period
$65.90M
YoY change
-31.8%
5Y CAGR
-20.7%
Peak year (2020)
$187.38M
Cumulative capital expenditures
$1.36B
CapEx history chart for Incyte (INCY) from 1993 to 2025
CapEx history table for Incyte (INCY) from 1993 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $58.87M | -31.8% | ||
| 2024 | $86.26M | +81.7% | ||
| 2023 | $47.49M | -39.0% | ||
| 2022 | $77.83M | -57.0% | ||
| 2021 | $181.01M | -3.4% | ||
| 2020 | $187.38M | +140.0% | ||
| 2019 | $78.06M | +6.2% | ||
| 2018 | $73.48M | -33.8% | ||
| 2017 | $111.02M | -7.7% | ||
| 2016 | $120.28M | +362.6% | ||
| 2015 | $26.00M | -6.7% | ||
| 2014 | $27.88M | +553.3% | ||
| 2013 | $4.27M | +50.3% | ||
| 2012 | $2.84M | -25.3% | ||
| 2011 | $3.80M | -7.5% | ||
| 2010 | $4.11M | +961.8% | ||
| 2009 | $387,000 | -44.6% | ||
| 2008 | $698,000 | -39.5% | ||
| 2007 | $1.15M | -26.5% | ||
| 2006 | $1.57M | -4.0% | ||
| 2005 | $1.63M | +17.4% | ||
| 2004 | $1.39M | -85.7% | ||
| 2003 | $9.74M | -18.1% | ||
| 2002 | $11.89M | -8.0% | ||
| 2001 | $12.92M | -86.6% | ||
| 2000 | $96.38M | +176.9% | ||
| 1999 | $34.80M | +0.3% | ||
| 1998 | $34.70M | +33.0% | ||
| 1997 | $26.10M | +29.2% | ||
| 1996 | $20.20M | +155.7% | ||
| 1995 | $7.90M | +203.8% | ||
| 1994 | $2.60M | +550.0% | ||
| 1993 | $400,000 | — |
CapEx values are taken from Incyte's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Incyte (INCY) capital expenditures is $58.87M – plunged 31.8% year-over-year.
Over 2020–2025 (5 years), Incyte capital expenditures expanded at a -20.7% compound annual rate, with a net decline across the window.
Incyte capital expenditures peaked at $187.38M in 2020; the latest annual figure is $58.87M in 2025 (68.6% below peak).
The highest annual capital expenditures of $187.38M was reported in 2020. The lowest in the available history was $387,000 in 2009.
Within Healthcare, Incyte (INCY) ranks 9th among 8 peers we track. The peer median for capital expenditures is $3.87B.
Incyte Capital Expenditures by Year
Incyte Capital Expenditures 2025: $58.87M
Incyte capital expenditures in 2025 was $58.87M, plunged 31.8% below 2024.
Incyte Capital Expenditures 2024: $86.26M
Incyte capital expenditures in 2024 was $86.26M, surged 81.7% from 2023.
Incyte Capital Expenditures 2023: $47.49M
Incyte capital expenditures in 2023 was $47.49M, plunged 39.0% below 2022.
Incyte Capital Expenditures 2022: $77.83M
Incyte capital expenditures in 2022 was $77.83M, plunged 57.0% below 2021.
Incyte Capital Expenditures 2021: $181.01M
Incyte capital expenditures in 2021 was $181.01M.
See more financial history for Incyte (INCY).
Sector peers — CapEx
Companies in the same sector as Incyte, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| AbbVie Inc. (ABBV) | $1.21B | Healthcare |
Frequently asked questions
What is Incyte's capital expenditures?
- Latest reported capital expenditures for Incyte (INCY) is $65.90M (period ending March 31, 2026).
How has Incyte capital expenditures changed year-over-year?
- Incyte (INCY) capital expenditures changed -31.8% year-over-year on the latest annual filing.
What is the long-term growth rate of Incyte capital expenditures?
- Incyte (INCY) capital expenditures compound annual growth rate is -20.7% over the most recent 5 years available.
When did Incyte capital expenditures hit its highest annual value?
- Incyte capital expenditures reached its highest annual value of $187.38M in 2020.
What was Incyte capital expenditures in 2024?
- Incyte (INCY) capital expenditures in 2024 was $86.26M.
What was Incyte capital expenditures in 2025?
- Incyte (INCY) capital expenditures in 2025 was $58.87M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
INCY Overview
Company profile, financial tools, and key metrics
INCY Revenue Counter
Earns $163.03 every second. See per minute, hour, and day.
INCY Earnings Counter
Earns $40.80 per second net profit. See per minute, hour, and day.
INCY Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
INCY What If Invested
What if you had invested $1,000? See historical returns from any date.
INCY How It Makes Money
Discover visual breakdown of $5.14B in revenue — where it comes from and where it goes.
INCY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INCY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INCY Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
INCY Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
INCY Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.